Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd has updated its Securities Trading Policy, as announced by the Board of Directors. This revision aligns with ASX Listing Rule 12.10 and reflects the company’s commitment to maintaining robust governance practices. The update is part of Cogstate’s ongoing efforts to enhance its operational framework, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to advance new medicine development and enable earlier clinical insights in healthcare. The company offers computerized cognitive tests and electronic clinical outcome assessment solutions, supporting clinical trials with quality assurance services and advanced analytics. Cogstate has been serving biopharmaceutical companies, academic institutions, and healthcare providers for over 20 years, with a notable partnership with Eisai for distribution in Asia.
YTD Price Performance: 65.55%
Average Trading Volume: 109,105
Technical Sentiment Signal: Buy
Current Market Cap: A$292.2M
Learn more about CGS stock on TipRanks’ Stock Analysis page.